Jaguar Health

Jaguar Health, Inc. is a commercial stage pharmaceuticals company, which engages in the development of gastrointestinal products. The firm focuses on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. It operates through the Human Health and Animal Health segments. The Human Health segment manufactures human products and the ongoing advertising of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The Animal Health segment commercializes prescription and non-prescription products for companion and production animals. The company was founded by Lisa A. Conte on June 6, 2013 and is headquartered in San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Jaguar Health reports revenue growth and eyes cancer therapy market

Jaguar Health's Q1 2024 performance showed revenue growth and improved financial metrics. The company's strategic focus on cancer supportive care and rare diseases positions it for future growth. Challenges include trial result uncertainties and regulatory timelines, but opportunities exist in market expansion and new programs.

Jaguar Health reports revenue growth and promising clinical trial results

Jaguar Health's Q2 2024 earnings call showcases revenue growth, positive clinical trial outcomes, and strategic plans for product launches and FDA discussions. The company's focus on improving patient outcomes and expanding its product reach positions it for future success in the healthcare market.

Jaguar Health reports revenue growth and advances in cancer care

Jaguar Health's Q3 performance reflects revenue growth, successful trial outcomes, and a focus on cancer patient care through innovative products.
While facing challenges in regulatory processes and financial metrics, the company is well-positioned to capitalize on opportunities in rare diseases and oncology.
Overall, Jaguar Health's strategic initiatives and commitment to addressing critical medical needs position it for potential growth and impact in the healthcare sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Jaguar Health, Inc. is a commercial stage pharmaceuticals company, which engages in the development of gastrointestinal products. It operates through the Human Health and Animal Health segments. The Human Health segment is involved in manufacturing human products and the ongoing advertising of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The Animal Health segment includes commercializing prescription and non-prescription products for companion and production animals. The company was founded by Lisa A. Conte on June 6, 2013 and is headquartered in San Francisco, CA.

Jaguar Health Inc (NASDAQ: JAGX) has signed a Memorandum of Understanding (MoU) with the lead sponsor of the planned Dragon special purpose acquisition company, pursuing a listing on AIM Italia. Per the MOU, Napo EU, the company's anticipated subsidiary in Italy, will be the named target of the Dragon SPAC and has granted latter exclusivity to list on AIM Italia and negotiate and finalize documentation for the contemplated merger transaction.

Jaguar Health In MoU With Dragon SPAC As Its Subsidiary Seeks Approval For Crofelemer In Europe

JAGX stock is on the move today after the popular company announced it had signed a memorandum of understanding for a SPAC deal. The post JAGX Stock: What to Know as SPAC News Sends Jaguar Health Soaring appeared first on InvestorPlace.

JAGX Stock: What to Know as SPAC News Sends Jaguar Health Soaring

JAGX stock holders must weigh the impact of an intriguing European SPAC and a potential treatment option for Covid-19 long-haul patients. The post Hold Jaguar Health Stock for SPAC Spin-Off and Covid-19 Connection appeared first on InvestorPlace.

Hold Jaguar Health Stock for SPAC Spin-Off and Covid-19 Connection

Churchill Capital Corp IV

Express

Koss

Cenntro Electric Group

Nokia

Palantir Technologies

SNDL Inc.

Zomedica

It may be fun to dabble in meme stocks. But, don't consider it a surefire path to investing profits.

9 Meme Stocks That Social Media Won't Shut Up About

The 12-month, 300% gain with JAGX stock has a lot of headline news. There's a lot to like, but will Jaguar be able to build on its gains?

Jaguar Health Has a Strong Outline, But the Story Is Unclear

Likely, no one would suggest that JAGX stock is a fundamentally sound investment. But the current market environment makes shares a compelling short-term trade.

Jaguar Health Isn't a Healthy Investment, but It Could Be a Profitable One

Jaguar Health stock is a speculative investment at best. JAGX stock is hard to nail down as it's hard to understand its numerous and strange financings.

Jaguar Health Stock Remains a Speculative Investment At Best

Jaguar Health might merge part of its Napo Pharmaceuticals unit with a SPAC. What's this mean for JAGX stock over the long haul?

Do We Know Enough About Napo Pharma's SPAC To Invest In Jaguar Health?

JAGX stock may be slumping today, but new SPAC merger news could turn things around. Here is what you should know about the Napo EU deal now.

JAGX Stock: Jaguar Health's Napo EU to Go Public Via SPAC

If you've been sitting on the sidelines when it comes to JAGX stock, an important meeting should give you the excuse you've been waiting for. The post Proposed SPAC Merger Makes Jaguar Health Stock Intriguing appeared first on InvestorPlace.

Proposed SPAC Merger Makes Jaguar Health Stock Intriguing

Jaguar Health is showing better vital signs lately. However, there are still some things to consider before pouncing on JAGX stock.

What You Need to Know About Jaguar Health Stock

Jaguar Health (JAGX) stock is on the rise Thursday after announcing a meeting concerning an upcoming SPAC merger in Italy. The post JAGX Stock Surges Ahead of Jaguar Health SPAC Merger Meeting appeared first on InvestorPlace.

JAGX Stock Surges Ahead of Jaguar Health SPAC Merger Meeting

The stock price of Jaguar Health Inc (NASDAQ: JAGX) has increased by over 15% pre-market today. This is why it happened.

JAGX Stock Price Increases Over 15% Pre-Market: Why It Happened

Ideanomics Inc

Marathon Digital Holdings

If the first week of 2021 is the sign of things to come this year, traders and investors are going to make a lot of money. 4 NASDAQ stocks that really lit up the first week of 2021 were Ideanomics (NASDAQ: IDEX), Jaguar Health (NASDAQ: JAGX), Marathon Patent Group (NASDAQ: MARA), and Riot Blockchain (NASDAQ: […]

4 Hot NASDAQ Stocks: Ideanomics (NASDAQ: IDEX), Jaguar Health (NASDAQ: JAGX), Marathon Patent Group (NASDAQ: MARA), and Riot Blockchain (NASDAQ: RIOT)

SAN FRANCISCO, CA / ACCESSWIRE / January 15, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today provided the replay link for the Company's January 14, 2021 investor webcast and a recap of the key points from the presentation. To access the audio recording and slides from the webcast, click here.

Jaguar Health Provides Replay Link & High-level Overview of January 14th Investor Webcast

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals (NASDAQ: REGN) shares are trading higher after the company announced an additional U.S. order to purchase 1.25 million doses of its COVID-19 antibody cocktail bringing the total number to over 1.5 million doses. Regeneron discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation.

Why Regeneron, Jaguar Health And Seneca Are Moving Today

This additional non-dilutive financing will support development program for lechlemer for the indication of the symptomatic relief of diarrhea and dehydration in cholera patients REMINDER: Jaguar-hosted investor webcast scheduled for Thursday, January 14 at 11:30 A.M. Eastern Time.

Jaguar Health Enters Non-dilutive Binding Term Sheet for $6.0 Million Sale of Partial Rights to Possible Tropical Disease Priority Review Voucher

SAN FRANCISCO, CA / ACCESSWIRE / January 13, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced it has entered into a securities purchase agreement with two institutional investors including a high-net-worth family office for the purchase and sale of 4,437,870 shares of common stock at a purchase price of $3.38 per share for gross proceeds of approximately $15.0 million in a registered direct offering priced above-the-market under Nasdaq rules. Ladenburg Thalmann & Co. Inc. is acting as exclusive placement agent in connection with the offering.

Jaguar Health Announces $15 Million Registered Direct Offering Priced Above-the-Market Under Nasdaq Rules

If you believe in the future of plant-based medical treatments, then a long position in JAGX stock could offer exposure to this technology. The post Don't Try to Tame Jaguar Health Stock As It Rips Higher appeared first on InvestorPlace.

Don't Try to Tame Jaguar Health Stock As It Rips Higher

REMINDER: Jaguar-hosted investor webcast scheduled for Thursday, January 14 at 11:30 A.M. Eastern Time.

Jaguar Health to Present at the H.C. Wainwright BIOCONNECT 2021 Virtual Conference the Week of January 11th and at 4:30 pm Eastern on Tuesday, January 19th at the NobleCon17 Virtual Conference

New COVID-19 strain estimated to have tripled number of infections in England during November 2020 lockdown Investor webcast scheduled for Thursday, January 14 at 11:30 A.M. Eastern Time.

Jaguar Health Exploring Possibility of Conditional Marketing Authorization for Proposed Inflammatory Diarrhea Indication for Crofelemer, Initially in ‘Long-Hauler' COVID-19 Recovery Patients in Europe

The developer of plant-based medicines has a promising drug pipeline.

Why Jaguar Health Stock Skyrocketed 49% Today

JAGX stock is on the move today as Jaguar Health continues to gain attention. Here's what you should know about the biopharma play now.

JAGX Stock: 11 Things to Know as Jaguar Health Rockets Higher

The stock price of Jaguar Health Inc (NASDAQ: JAGX) increased over 20% shortly after the market opened this morning. This is why it happened.

JAGX Stock Price Increased Over 20%: Why It Happened

Lechlemer development focused on possible tropical disease priority review voucher SAN FRANCISCO, CA / ACCESSWIRE / January 6, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") announced today that the 28-day preclinical toxicology and safety study in dogs began today, January 6, 2021, to support development of lechlemer, the second generation, plant-based anti-secretory drug candidate of Napo Pharmaceuticals ("Napo"), Jaguar's wholly owned subsidiary, for the symptomatic relief of diarrhea from cholera. As previously announced, Napo is receiving preclinical services from the National Institute of Allergy and Infectious Diseases ("NIAID") to support lechlemer development.

Jaguar Health Subsidiary Receiving Preclinical Services from the National Institute of Allergy and Infectious Diseases for New Preclinical Study Initiated January 6, 2021 for Lechlemer Plant-Based Drug Candidate for the Symptomatic Relief of Diarrhea from

News for Jaguar Health Stock (JAGX)